A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Shortt, Jake (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA Reference Number: HREC/16/MonH/50
NMA SSA Reference: SSA/16/MonH/101
Monash Health HREC Ref: 16150A

Status	Active
Effective start/end date	30/08/19 → 29/08/24

Keywords

clinical trial
phase 3 study
treatment efficacy
blood cancers